Gilead Sciences
GILD
$65.59
Share price
0.49%
Change (1 day)
-23.37%
Change (1 year)
Categories
Gilead Sciences (GILD) - Cash on Hand
Cash on Hand as of December 2023 : $7.26 B
According to Gilead Sciences's latest financial reports the company has $7.26 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Gilead Sciences - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $7.26 B | 13.77% |
| 2022-12-31 | $6.38 B | -2.07% |
| 2021-12-31 | $6.52 B | -11.99% |
| 2020-12-31 | $7.40 B | -69.58% |
| 2019-12-31 | $24.35 B | -19.07% |
| 2018-12-31 | $30.08 B | 17.95% |
| 2017-12-31 | $25.51 B | 114.46% |
| 2016-12-31 | $11.89 B | -18.57% |
| 2015-12-31 | $14.60 B | 44.22% |
| 2014-12-31 | $10.12 B | 375.05% |
| 2013-12-31 | $2.13 B | 14.49% |
| 2012-12-31 | $1.86 B | -81.19% |
| 2011-12-31 | $9.90 B | 371.74% |
| 2010-12-31 | $2.09 B | 26.66% |
| 2009-12-31 | $1.65 B | -7.43% |
| 2008-12-31 | $1.79 B | 52.74% |
| 2007-12-31 | $1.17 B | 25.1% |
| 2006-12-31 | $0.93 B | -59.46% |
| 2005-12-31 | $2.31 B | 84.29% |
| 2004-12-31 | $1.25 B | 77.37% |
| 2003-12-31 | $0.70 B | -24.98% |
| 2002-12-31 | $0.94 B | 61.68% |
| 2001-12-31 | $0.58 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $22.92 B | 215.63% | 🇺🇸 USA |
 Pfizer PFE | $12.69 B | 74.70% | 🇺🇸 USA |
 AbbVie ABBV | $12.81 B | 76.43% | 🇺🇸 USA |
 Eli Lilly LLY | $2.92 B | -59.70% | 🇺🇸 USA |
 Amgen AMGN | $10.94 B | 50.66% | 🇺🇸 USA |
 Biogen BIIB | $1.04 B | -85.55% | 🇺🇸 USA |
 Illumina ILMN | $1.05 B | -85.49% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | $11.21 B | 54.44% | 🇺🇸 USA |
 Merck MRK | $7.09 B | -2.35% | 🇺🇸 USA |